Gain Therapeutics’ (GANX) “Buy” Rating Reaffirmed at HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 380.48% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, June 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Friday, September 4th. Finally, BTIG Research reaffirmed a “buy” rating and set a $5.00 target price on shares of Gain Therapeutics in a research note on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Gain Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

Gain Therapeutics Price Performance

GANX traded down $0.01 during trading on Monday, hitting $1.67. 319,111 shares of the company traded hands, compared to its average volume of 729,354. The company has a market cap of $72.66 million, a PE ratio of -3.33 and a beta of 0.19. The stock’s 50-day simple moving average is $1.83 and its two-hundred day simple moving average is $1.83. Gain Therapeutics has a 1 year low of $1.53 and a 1 year high of $4.34. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.02.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. As a group, sell-side analysts anticipate that Gain Therapeutics will post -0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in GANX. Potomac Capital Management Inc. purchased a new position in shares of Gain Therapeutics during the 4th quarter worth about $3,252,000. GSA Capital Partners LLP purchased a new position in shares of Gain Therapeutics during the 2nd quarter worth about $1,283,000. BlackRock Inc. purchased a new position in shares of Gain Therapeutics during the 2nd quarter worth about $558,000. Squarepoint Ops LLC purchased a new position in shares of Gain Therapeutics during the 2nd quarter worth about $277,000. Finally, Apollon Wealth Management LLC boosted its stake in shares of Gain Therapeutics by 33.7% during the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after purchasing an additional 6,675 shares during the period. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. Its research focuses on correcting the activity of misfolded or dysfunctional lysosomal enzymes, which are implicated in conditions involving the accumulation of toxic cellular material.

The company uses a structure-based drug discovery platform designed to identify previously unrecognized binding sites on disease-related proteins.